Skip to content
Trafermin
Trafermin is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
D03: Preparations for treatment of wounds and ulcers
D03A: Cicatrizants
D03AX: Other cicatrizants in atc
D03AX15: Trafermin
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PeriodontitisD010518EFO_0000649K05.3224
Diabetic footD017719EFO_100145922
Tympanic membrane perforationD018058H7211
Alveolar bone lossD01630111
Periodontal attachment lossD01762211
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRAFERMIN
INNtrafermin
Description
Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers. It is also currently in preregistration for the treatment of periodontitis. As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4. The drug has been marketed in Japan since June 2001.
Classification
Protein
Drug classgrowth factors: fibroblast growth factors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID131094-16-1
RxCUI
ChEMBL IDCHEMBL2108081
ChEBI ID
PubChem CID
DrugBankDB06244
UNII ID333OX80X87 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 119 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details